JNJ-4528

Unassigned

New Medicines

Relapsed/refractory multiple myeloma (MM) in adults whose prior regimens included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody

Information

Advanced therapy medicinal product (ATMP)
Janssen
Johnson & Johnson

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

JNJ-4528 consists of autologous chimeric antigen receptor T (CAR-T) cells designed to treat relapsed or refractory multiple myeloma. The target antigen is B cell maturation antigen (BCMA). Given as a single infusion.
Multiple myeloma is the second most common haematological cancer. It is responsible for 15-20% of deaths from haematological cancer and about 2% of all deaths from cancer. The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1].
Relapsed/refractory multiple myeloma (MM) in adults whose prior regimens included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody
Intravenous infusion

Relapsed/refractory multiple myeloma (MM) after 1 to 3 prior therapies

Information

Advanced therapy medicinal product (ATMP)
Janssen
Johnson & Johnson

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

JNJ-4528 consists of autologous chimeric antigen receptor T (CAR-T) cells designed to treat relapsed or refractory multiple myeloma. The target antigen is B cell maturation antigen (BCMA). Given as a single infusion.
Multiple myeloma is the second most common haematological cancer. It is responsible for 15-20% of deaths from haematological cancer and about 2% of all deaths from cancer. The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1].
Relapsed/refractory multiple myeloma (MM) after 1 to 3 prior therapies
Intravenous infusion